Shareholders' Equity (Details)		9 Months Ended	12 Months Ended
	Nov. 03, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) Plan $ / shares shares	Mar. 31, 2015 USD ($) $ / shares shares
Securities Purchase Agreement [Abstract]
Common stock issued (in shares)		26,057,327	60,436,548
Net proceeds from common stock issuance | $		$ 0	$ 23,428,900
Share-based compensation expense | $		$ 979,000	748,000
Restricted shares and warrants, additional disclosures [Abstract]
Unrecognized share-based compensation expense | $			$ 743,000
Unrecognized compensation expense, weighted average period of recognition			1 year 6 months
Warrants issued to purchase common stock (in shares)		376,123
Warrants exercise price (in dollars per share) | $ / shares		$ 9.31
Accelmed [Member]
Securities Purchase Agreement [Abstract]
Common stock issued (in shares)	16,129,033
Common stock issued price (in dollars per share) | $ / shares	$ 1.55
Gross proceeds from common stock issuance | $	$ 25,000,000
Net proceeds from common stock issuance | $	23,429,000
Common stock issuance expense | $	$ 1,571,000
Stock Options [Member]
Weighted-average assumptions used to value the options granted [Abstract]
Expected life, in years		3 years 10 months 2 days	3 years 10 months 24 days
Risk-free interest rate		1.11%	0.98%
Expected volatility		63.90%	61.86%
Expected dividend yield		0.00%	0.00%
Stock options, number of shares [Roll Forward]
Outstanding, beginning of period (in shares)		2,250,865	2,573,640
Options granted (in shares)		617,914	692,400
Options exercised (in shares)		0	0
Options surrendered (in shares)		(295,139)	(1,585,050)
Outstanding, end of period (in shares)		2,573,640	1,680,990	2,250,865
Exercisable, end of period (in shares)			811,015
Stock options, weighted average exercise price [Roll Forward]
Outstanding, beginning of period (in dollars per share) | $ / shares		$ 5.32	$ 4.46
Options granted (in dollars per share) | $ / shares		1.64	1.05
Options surrendered (in dollars per share) | $ / shares		5.08	3.90
Outstanding, end of period (in dollars per share) | $ / shares		4.46	3.54	$ 5.32
Exercisable, end of period (in dollars per share) | $ / shares			3.80
Stock options, additional disclosures [Abstract]
Weighted-average grant date fair value (in dollars per share) | $ / shares		$ 0.79	$ 0.49
Outstanding, Aggregate intrinsic value, beginning of period | $		$ 0	$ 0
Outstanding, Aggregate intrinsic value, end of period | $		$ 0	752,290	$ 0
Exercisable, Aggregate intrinsic value, end of period | $			$ 607,800
Outstanding, Weighted average remaining life in years		5 years 2 months 26 days	6 years 6 months 18 days	5 years 22 days
Options exercisable, Weighted average remaining life in years			3 years 8 months 16 days
Fair value of stock options vested | $		$ 519,000	$ 276,000
Proceeds from stock options exercised | $		$ 0	$ 0
Stock Options [Member] | Executive Employees and Directors [Member]
Weighted-average assumptions used to value the options granted [Abstract]
Forfeiture rate			15.00%
Stock Options [Member] | Non-Executive Employees [Member]
Weighted-average assumptions used to value the options granted [Abstract]
Forfeiture rate			20.00%
Restricted Stock [Member]
Restricted shares and warrants, number of shares [Roll Forward]
Balance, beginning of period (in shares)		317,741	686,910
Shares granted (in shares)		513,299	937,858
Shares vested (in shares)		(122,353)	(324,521)
Shares surrendered (in shares)		(21,777)	(307,699)
Balance, end of period (in shares)		686,910	992,548	317,741
Restricted shares, weighted average grant date fair value [Roll Forward]
Balance, beginning of period (in dollars per share) | $ / shares		$ 4.47	$ 2.41
Shares granted (in dollars per share) | $ / shares		1.62	1.18
Shares vested (in dollars per share) | $ / shares		4.42	2.19
Shares surrendered (in dollars per share) | $ / shares		2.73	2.45
Balance, end of period (in dollars per share) | $ / shares		$ 2.41	$ 1.30	$ 4.47
Restricted shares and warrants, additional disclosures [Abstract]
Weighted average remaining life in years, Balance		1 year 7 months 2 days	1 year 4 months 6 days	1 year 11 months 5 days
Aggregate intrinsic value, Balance | $		$ 387,644	$ 886,114
Shares vested, Aggregate intrinsic value | $		157,835	652,287
Aggregate intrinsic value, Balance | $		$ 886,114	$ 1,995,021	$ 387,644
Restricted Stock [Member] | Minimum [Member]
Securities Purchase Agreement [Abstract]
Vesting period			6 months
Restricted Stock [Member] | Maximum [Member]
Securities Purchase Agreement [Abstract]
Vesting period			1 year
2015 Plan [Member]
Securities Purchase Agreement [Abstract]
Number of active plans for share-based compensation grants | Plan			1
Number of shares reserved for share-based grants (in shares)			2,500,000
Shares remain available for grant (in shares)			1,377,130
Vesting period			2 years
Stock options, number of shares [Roll Forward]
Outstanding, end of period (in shares)			1,680,990
2015 Plan [Member] | Stock Options [Member]
Securities Purchase Agreement [Abstract]
Vesting period			3 years
2015 Plan [Member] | Stock Options [Member] | Minimum [Member]
Securities Purchase Agreement [Abstract]
Term of share-based payment award			5 years
2015 Plan [Member] | Stock Options [Member] | Maximum [Member]
Securities Purchase Agreement [Abstract]
Term of share-based payment award			7 years
2006 Plan [Member] | Performance Award [Member]
Restricted shares and warrants, additional disclosures [Abstract]
First stock price target of common stock (in dollars per share) | $ / shares			$ 7.57
Second stock price target of common stock (in dollars per share) | $ / shares			10.32
Third stock price target of common stock (in dollars per share) | $ / shares			$ 13.76